Christopher D. Ozeroff's most recent trade in Oruka Therapeutics Inc. was a trade of 27,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 14, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oruka Therapeutics Inc. | Christopher D. Ozeroff | S.V.P., General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 27,500 | 27,500 | - | - | Stock Option (right to buy) | |
| Oruka Therapeutics Inc. | Christopher D. Ozeroff | S.V.P., General Counsel | Purchase of securities on an exchange or from another person at price $ 2.26 per share. | 22 Nov 2021 | 50,000 | 50,970 (3%) | 3% | 2.3 | 113,210 | Common Stock |
| Oruka Therapeutics Inc. | Christopher D. Ozeroff | S.V.P., General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 55,000 | 55,000 | - | - | Stock Option (right to buy) |